DeepSeek blew up markets year ago. Why hasn't it done so since?

Original Article Summary
Nearly a year on from the Chinese AI company shaking the tech world, CNBC digs into why DeepSeek's recent model releases haven't caused the same frenzy.
Read full article at CNBC✨Our Analysis
DeepSeek's failure to replicate the market frenzy of its initial release, despite subsequent model releases, highlights the company's struggle to sustain investor excitement. The Chinese AI company's initial breakthrough sent shockwaves through the tech world, but its recent efforts have been met with relatively muted responses. For website owners, this means that the anticipated surge in AI bot traffic from DeepSeek's models has not materialized, allowing them to focus on optimizing their sites for more established AI players. This also means that website owners can breathe a sigh of relief, as the potential for DeepSeek's models to overwhelm their sites with traffic has decreased. However, it is still crucial for website owners to monitor AI bot traffic and adjust their llms.txt files accordingly to ensure they are not inadvertently blocking or allowing unwanted bot traffic. To stay ahead, website owners should regularly review their llms.txt files to ensure they are up-to-date with the latest AI bot signatures, including those from DeepSeek. Additionally, they should consider implementing AI bot tracking tools to monitor traffic patterns and adjust their strategies as needed. Lastly, website owners should stay informed about developments in the AI landscape, including updates from DeepSeek and other key players, to anticipate and prepare for potential changes in AI bot traffic.
Track AI Bots on Your Website
See which AI crawlers like ChatGPT, Claude, and Gemini are visiting your site. Get real-time analytics and actionable insights.
Start Tracking Free →Related Articles

RENDER outpaces LINK and TAO with 21% rally – Watch THIS closely!
1/7/2026

Using Python notebooks to save money in Fabric: The Fabric Modern Data Platform
1/7/2026

Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial
1/7/2026
